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Abstract 
The role of estrogen sulfotransferase in ischemic acute kidney injury 
 
Anne Caroline Silva Barbosa, PhD 
 
University of Pittsburgh, 2020 
 
 
 
 
Acute kidney injury (AKI) is a sudden impairment of kidney function. It has been 
suggested that estrogens may protect mice from AKI. Estrogen sulfotransferase (SULT1E1/EST) 
plays an important role in estrogen homeostasis by sulfonating and deactivating estrogens, but the 
role of SULT1E1 in AKI has not been previously reported.  
In this dissertation, Wild-type (WT) mice, Sult1e1 knockout (Sult1e1 KO) mice, and 
Sult1e1 KO mice with hepatic reconstitution of Sult1e1 were subjected to a bilateral kidney 
ischemia-reperfusion model of AKI, in the absence or presence of gonadectomy. Kidney injury 
was assessed at biochemical, histological and gene expression levels. WT mice treated with the 
Sult1e1 inhibitor triclosan were also used to determine the effect of pharmacological inhibition of 
Sult1e1 on AKI. Results showed that AKI induces the expression of Sult1e1 in a tissue- and sex-
specific manner, inducing the hepatic expression of Sult1e1 in both male and female mice, but the 
kidney induction of Sult1e1 was only observed in male mice. A deeper investigation further 
demonstrated that (1) genetic knockout or pharmacological inhibition of Sult1e1 protects mice of 
both sexes from AKI in a sex hormone-independent manner. (2) Moreover, the effect of Sult1e1 
on AKI is also tissue- and sex-specific, because transgenic reconstitution of Sult1e1 to the liver of 
Sult1e1 KO mice abolishes the protection in male mice, but not in female mice.  
Finally, it was observed that the protective effect of Sult1e1 ablation is possibly associated 
with increased vitamin D receptor signaling. Overall, this dissertation elucidates a novel function 
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of Sult1e1 in the pathogenesis of AKI. Sult1e1 inhibitors may have their therapeutic utility in the 
clinical management of AKI. 
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1.0 Introduction 
1.1 AKI 
Acute kidney injury (AKI) is defined by the Kidney Disease: Improving Global Outcomes 
(KDIGO) criteria as an abrupt impairment of kidney function manifested by high levels of serum 
creatinine (1.5–1.9 times baseline, or ≥ 0.3 mg/dl) and/or reduced urine output (0.5 ml/kg/h for 6–
12 hours) (Table 1) [1]. The AKI syndrome is common in critically ill patients and is associated 
with increased length of hospitalization, morbidity, chronic kidney disease, and mortality [2]. The 
etiology of AKI includes pre-kidney (loss of blood flow to the kidney), intrinsic (direct damage to 
the organ), and post-kidney (obstruction of the lower urinary system) causes (Table 2) [1-3].  
 
Table 1: Staging of AKI: KDIGO.  
 
STAGE SERUM CREATININE URINE OUTPUT 
1 1.5-1.9 times baseline OR ≥ 0.3 mg/dl (≥ 26.5 
nmol/l) increase 
< 0.5 ml/kg/h for 6-12 
hours 
2 2.0-2.9 times baseline < 0.5 ml/kg/h for ≥ 12 
hours 
3 3.0 times baseline OR increase in serum creatinine 
≥ 4.0 mg/dl (≥ 353.6 µmol/l) OR initiation of 
kidney replacement therapy (KRT) OR, in patients 
< 18 years, decrease in eGFR to < 35 ml/min per 
1.73 m2 
< 0.3 ml/kg/h for ≥ 24 
hours OR anuria for ≥ 12 
hours 
        Adapted from [1, 4].   
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Table 2: Causes of AKI.  
CAUSES OF AKI 
PRE-KIDNEY INTRINSIC POST KIDNEY 
Ischemia  
Hemorrhage 
Heart attack 
Heart disease 
Liver failure 
Severe burns/dehydration 
Use of NSAIDs  
Severe allergic reaction 
 
Blood clots in the kidney’s 
veins and arteries 
Cholesterol deposits 
Glomerulonephritis 
Antibiotics 
Certain chemotherapies 
Toxins (e.g. alcohol) 
Heavy metals  
Cocaine 
 
Urinary tract obstruction 
at any site downstream the 
kidney.  
(e.g. stones,  
tumor, and 
prostatic enlargement) 
 
Adapted from [1, 4]. 
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Figure 1: Illustration of bilateral kidney ischemia-reperfusion. 
 
Understanding the pathophysiology of AKI will facilitate the development of novel 
strategies to manage this disease. The bilateral kidney warm ischemia-reperfusion is a widely used 
mouse model of AKI [5].  For this approach, a midline incision is performed dorsally in a mouse 
anesthetized with 90mg/kg ketamine and 10mg/kg xylazine. Using heatpad or heatblock, the 
animal’s body temperature is controlled at 37ºC. Left and right kidney pedicles are then obstructed 
for 30 minutes using metallic clamps, as in Figure 1. During ischemia, the kidneys turn into a 
darker color. Mice are closely monitored throughout that period and dryness is avoided by covering 
the abdominal cavity with phosphate buffer saline (PBS) embedded gauze. Once the 30 minutes 
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have been reached the clamps are removed, the kidneys are reperfused with blood flow and 
gradually turn into a red color, darker than natural [6] due to inflammatory activation.  
 
Inflammation plays an important role in AKI pathophysiology. In the initial phase of AKI, 
renal vascular endothelial cells affected by IRI interact with injurious agents that disrupt the 
endothelial wall. This loss of cellular adhesion results in increased vascular permeability and 
enables leukocyte (neutrophil, macrophage, lymphocyte, natural killer cells, and dendritic cells) 
infiltration [7]. Next, reactive oxygen species (ROS) stimulate the production of interferon 
regulatory factor-1 (IRF-1) –a transcription factor that stimulates expression of proinflammatory 
genes– in the S3 portion of renal tubular cells [8]. Kidney injury marker-1 (KIM-1), an 
immunoglobulin superfamily cell surface molecule produced in epithelial tubule cells after IRI is 
then rapidly increased. Kim-1 converts epithelial cells into phagocytes that engulf apoptotic and 
necrotic cells [9]. Tubule cells and leukocytes then release proinflammatory cytokines, such as 
interferon-gamma (IFNγ), Interleukins (IL) 2,10, and 6, and transforming growth factor-beta 
(TGF-ß) [10, 11]. Cytokines, complement, ROS, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-KB) system, and toll-like receptor (TLR)-related pathways stimulate 
chemokines, such as chemokine ligand-1 (CXCL1), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), macrophage inflammatory protein 2 (MIP-2), and monocyte chemoattractant 
protein-1 (MCP-1) [10-12]. All these contribute to the resulting AKI injury. 
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The clinical management of AKI is comprised of fluid support and agents to prevent life-
threatening nutritional and hemodynamic changes, but no specific pharmacological treatment for 
AKI has been approved [1]. To avoid acidosis, electrolyte alterations, uremia, and fluid 
accumulation, the KDIGO criteria suggest discontinuing agents toxic to kidneys, controlling fluid 
overload, monitoring disease markers, and consuming a total of 20 to 30kcal/kg/day in patients of 
any AKI stage. At later stages, it is suggested to evaluate the medication regimen, consider 
admission at the intensive care unit (ICU), and artificial kidney filtration. Finally, at the last stage, 
subclavian catheters should be avoided because of the high incidence of subclavian stenosis in this 
group [1] (Table 3).   
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Table 3: AKI Management.  
AKI STAGE 
HIGH RISK STAGE 1 STAGE 2 STAGE 3 
Discontinue all agents toxic to kidneys when possible 
Ensure volume status and pressure  
Consider functional hemodynamic monitoring 
Monitor serum creatinine and urine output 
Avoid hyperglycemia 
Consider alternatives to radiocontrast procedures 
 Non-invasive diagnostic workup 
 Consider invasive diagnostic workup 
  Check for changes in drug dosing 
  Consider kidney replacement therapy 
  Consider ICU admission 
   Avoid subclavian catheters if 
possible 
Adapted from [1, 4]. 
 
Besides its kidney effect, AKI has been reported to affect many distal organs, including the 
liver. The accumulation of uremic toxins, an imbalance between acid and alkaline molecules, 
electrolyte imbalance, inflammation, oxidative stress, and neurohormonal dysfunction are 
responsible for impairing the function of organs such as the brain, immune system, intestine, lung, 
liver, and heart (Figure 2) [13, 14].  
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AKI may, sometimes, resolve without complications. In a cohort study, 26.6% of AKI 
patients recovered within a 7-days hospitalization. However, relapses were common and their 1-
year mortality after hospital discharge reached 10% [15]. Therefore, AKI commonly progresses to 
chronic kidney disease (CKD). CKD development was observed in 24.6% of a cohort followed-
up for three years after hospital admission [16]. Moreover, controlled CKD may once again turn 
acute. Consequently, both AKI and CKD may progress to kidney failure. The complications of 
kidney failure comprise, especially, the cardiac and pulmonary systems. It is estimated that kidney 
failure has a prevalence of approximately 2100 per million people in the US population and it is 
expected that by 2030 this prevalence may increase up to 70% [17]. Therefore, it is crucial to find 
a specific drug target to treat AKI.  
Each year in the United States, the need for dialysis is increased by 10% in comparison to 
the previous year. This high incidence is especially associated with male sex, black race, and older 
age. Sepsis, cardiac complications, and mechanical respiration were responsible for a third of cases 
that required dialysis [18]. Continuous kidney replacement therapy (CRRT), the leading form of 
RRT, comprises hemofiltration, which stands for treatment with a replacement fluid that is 
combined with the blood and enables clearance, this solution is then ultrafiltered by a 
semipermeable membrane at an effluent flow rate of 20–25 ml/kg per h and returned to the patient 
[19]. Nonetheless, the overall patient survival rate is below 60%, especially among pediatric 
patients [20]. 
Kidney transplantation is a common outcome in kidney failure patients. Although the 
number of successful transplants are increasing each year, approximately four thousand people die 
annually on the wait-list [21].  However, up to three years after transplanting the new organ, 
approximately 11% of patients develop new episodes of AKI, principally those at the early stages 
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of CKD. As far as 90 days after an AKI hospitalization of kidney transplanted patients, transplant 
loss for any reason, death with a working transplant, and death-censored transplant failure 
happened to 26.3%, 11.4%, and 14.9% of AKI patients, respectively [22]. These issues can be 
partially accounted for by subclinical kidney injury in deceased donors. Reese et al. (2016) 
demonstrated that five urinary biomarkers of AKI, such as NGAL, interleukin 18 (IL-18), KIM-1, 
microalbumin, and liver-type fatty acid-binding protein (L-FABP) were elevated in 9% of these 
donors while creatinine was still low. The transplant loss can also be accounted for by stressful 
events preceding organ donation that lead to kidney damage, such as brain trauma, hypotension, 
and administration of compounds toxic to kidneys during hospitalization. Moreover, organ 
recipients of a kidney with AKI acquire delayed graft function and have a 40% increased risk of 
graft loss within 1 year of transplantation, as the allograft damage culminates with immune cell 
infiltration, inflammation, interstitial fibrosis, tubular atrophy, and glomerulosclerosis  [21]. 
Therefore, there are many risks associated with kidney replacement therapy and kidney 
transplantation. Identifying and treating AKI at the early stages is paramount to prevent serious 
complications that may become irreversible. 
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Figure 2: The impact of AKI on distant organs.  
Adapted from [14]. 
 
Understanding how AKI impairs distant organs at early stages is paramount to prevent the 
occurrence of complications. In the liver, AKI may lead to increased levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), and impaired activity of multiple 
drug metabolizing enzymes (DMEs) via increased inflammation, apoptosis, and oxidative stress 
[23-25]. Most of the reported effects of AKI on DMEs are focused on the phase I cytochrome P450 
enzymes [25], whereas the AKI effect on the expression and activity of the phase II conjugating 
enzymes is largely unknown. 
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1.2  Phase II enzymes 
Metabolism is a crucial mechanism to inactivate and excrete both endobiotics and 
xenobiotics. This process occurs in the gut, liver, and kidneys, and is divided into hydrolytic and 
oxide redox (Phase I) reactions, as well as conjugation reactions (Phase II). The phase I enzymes 
are responsible for N- and O-dealkylation, aliphatic and aromatic hydroxylation, N- and S-
oxidation, and deamination of any lipophilic compounds. Ester hydrolases and the cytochrome 
P450 enzymes are involved primarily in the hydroxylation, the latter being the most important and 
extensively studied phase I enzymes [26].  
The phase II enzymes also play a crucial role in drug metabolism. These enzymes are 
responsible for the conjugation of oxidized or hydrolyzed compounds, therefore making them 
more hydrosoluble and suitable for excretion. Phase II enzymes are mostly transferases that 
transfer small molecular weight, organic donor molecules such as 3-phosphoadenosine 5’-
phosphosulfate (PAP)-sulfate, glutathione, UDP-glucuronic acid, or acetyl-coenzyme A [26-29]. 
These conjugation reactions are catalyzed by PAPS-sulfotransferase (SULT), glutathione S-
Transferase (GST), UDP-glucuronosyltransferase (UGT), and N-Acetyltransferase (NAT).  
1.2.1 Sulfotransferases, their functions and tissue distributions 
Sulfotransferases (SULT) comprise a gene family of enzymes responsible for catalyzing  
reversible sulfation of low molecular weight compounds via the transfer of a negatively charged 
sulfonate group (SO3-) from the universal donor 3-phosphoadenosine 5’-phosphosulfate (PAPS) 
to a nucleophilic group of their substrates [30-36]. PAPS is produced by the reaction between 
inorganic sulfate, uptake from the extracellular medium to the cytosol [35],  and two molecules of 
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ATP, which can be mediated by both ATP sulfurylase and two forms of adenosine 5’-
phosphosulfate kinase (APS kinases), PAPSS1 and PAPSS2 [30-32, 36]. Both PAPS and APS 
kinases are conserved among species and their absence culminates with lethality because 
sulfotransferases are vital for homeostasis [36, 37]. SULT enzymes are divided into membrane-
bound, Golgi-residing [34, 38], and soluble cytosolic enzymes [34]. The Golgi-located SULTs 
conjugate proteins, carbohydrates, and proteoglycans, whereas the cytosolic enzymes sulfate 
essentially small hydrophobic molecules, such as phenols, xenobiotics (including drugs, dietary 
chemicals, and environmental contaminants [36, 39]) and steroids [34, 36, 39]. Although some 
sulfated chemicals remain metabolically active, sulfation is majorly a vital step for detoxification 
and reduction of biological activity, as it increases hydrosolubility, enabling the molecule to be 
excreted from the body via urine and/or bile [39]. At least thirteen isoforms of human cytosolic 
SULTs have been identified [30, 33, 40], but out of those, SULT1 and SULT2 families are 
responsible for sulfonating the largest number of xeno and endobiotics, making them the most 
important isoforms for drug metabolism [30, 33, 34, 36]. Their isoforms comprise phenol 
sulfotransferases (SULT1A1 and SULT1A2), catecholamine phenol sulfotransferase (SULT1A3/4), 
thyroid hormone sulfotransferase (SULT1B1), estrogen sulfotransferase (SULT1E1), and 
hydroxysteroid sulfotransferase (SULT2A1) [39]. For the substrates, SULT 1A1 and 1A2 are 
responsible for the metabolism of phenolic compounds, whereas SULT1A3/4 is responsible for the 
conjugation of catecholamines. SULT1B1 conjugates the thyroid hormone substrates, tyrosine, and 
DOPA, whereas SULT2A1 and SULT1E1 have steroid substrates, with estrogens as the preferred 
substrates of SULT1E1 [41]. The expression of SULT1 and SULT2 isoforms vary among tissue 
types, and the expression is subject to the regulation by tissue development and hormonal influence 
[30, 33, 34]. 
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Among SULTS, SULT1A1 is one of the most studied SULT isoforms. It has been suggested 
that polymorphisms in its gene may have accounted for variations in inter-individual susceptibility 
to cancers [30, 32, 33] due to the fact that SULT1A1 activates environmental mutagens and 
carcinogens found in well-done meat [30, 33, 40]. A study conducted by Riches et al. analyzed the 
expression of all major human SULTS within different organs. Their results demonstrated that out 
of all human hepatic SULT enzymes, 53% of them are SULT1A1, followed by SULT2A1 (27%), 
SULT1B1 (14%), and SULT1E1 (6%). In the gastrointestinal tract, SULT1B1 accounted for 36% 
of all SULTs, followed by SULT1A3 (31%), SULT1A1 (19%), SULT1E1 (8%), and SULT2A1 
(6%). In the same report, the authors also observed that SULT1E1 was the main isoform expressed 
in the lung (40%), with a lower expression of SULT1A1 (20%), SULT1A3 (19%), SULT1B1 (12%), 
and SULT2A1 (9%). Meanwhile, SULT1A1, SULT1B1, and SULT1A3 were abundantly expressed 
in the kidney, constituting 40, 31, and 28% of all SULTs, respectively [39]. Although the kidney 
expression of SULT1E1 was not detectable in the study, Miki et al. have previously shown that 
this enzyme is also expressed in the tubular cells of the human kidney, and in several other tissues, 
including trachea, lung, esophagus, spleen, pancreas, adkidney gland, thyroid, urinary bladder 
[42], as well as placenta, testis, and ovaries [43, 44]. On the other hand, the evaluation of SULT 
tissue distributions in mice showed some discrepancies compared to the human isoforms. As 
reported by Alnouti and colleagues, the Sult1e1 mRNA was only expressed in the gonadal organs 
[45]. In contrast to their findings, several studies have since been published showing that Sult1e1 
is expressed in mouse extragonadal tissues, such as the liver and adipose tissue [46-49], whereas 
recent findings suggest it may also be expressed in the mouse kidney [50].  
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1.3  SULT1E1 
The circulating estrogens are predominantly synthesized in premenopausal women’s 
ovaries. Upon menopause, the ovary discontinues the estrogen production, but extragonadal tissues 
such as the breast [51], adipose tissue, and brain maintain the production of estrogens. In males as 
well as females, testosterone and androstenedione can serve as substrates of the brain and testis 
CYP19A1 enzyme (aromatase) to synthesize estrogens [52]. Most, if not all, the cellular effects of 
estrogens are mediated by the nuclear receptors estrogen receptor alpha (ERα) and -beta (ERß) 
with a high ligand-receptor binding affinity (Kd ˜1nM)  [53-55]. Although estrogens, namely 
estradiol (E2) and estrone (E1), have been reported to be the substrates of multiple SULTs 
including SULT1A1 and SULT2A1 [56], SULT1E1 exhibits the highest affinity for these 
hormones, especially the 3-hydroxyl position of E2 [30, 55], to which it binds with a Michaelis-
Menten constant (Km) of 0.27 nM and with a turnover number (kcat) of 10s-1x103/nM respectively 
[57, 58]. This sulfoconjugation of estrogens can be reversed by the deconjugation reaction 
catalyzed by the steroid sulfatase (STS) [59].  
In COS-1 cells, SULT1E1 was able to sulfoconjugate dehydroepiandrosterone (DHEA), 
but with a low affinity of 850 nM [60]. Interestingly, at the concentration of 1.8 nM E1 is sulfonated 
by SULT1E1; however, at 40 nM this compound inhibits the Sult1e1 activity [58, 61]. The structure 
of SULT1E1 is majorly formed by an α/ß motif that comprises a ß sheet of five parallel ß-strands 
involved by two lateral α-helices and a preserved helix, which accommodate the PAPS binding 
site [62]. Petrotchenko and colleagues demonstrated that through van der Waals interactions, E2 
firmly adheres to the Tyr-81/Phe-142 residues of SULT1E1 and is placed horizontally in the 
cylindrical hydrophobic binding pocket. The enzyme then transfers the 5’-sulfate of PAPS to the 
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3’-phenolic hydroxyl group of E2 [57]. Mutations in these residues lead to reduced E2 sulfonation 
[57].  
A ligand-binding study performed by Zhang et al. showed that two different molecules of 
E2 may independently attach to the SULT1E1 binding pocket, either via an allosteric or a catalytic 
site, suggesting a random Bi Bi mechanism with two dead-end complexes [55]. The resulting 
sulfonated estrogens are more hydrosoluble, the 1-octanol/water partition coefficients (PC) of E2 
and E2-sulfate are 490 and <0.01, respectively [33, 63]. Therefore, sulfonated estrogens are unable 
to bind the receptors located inside the hydrophobic nuclear envelope and thus lose their hormonal 
activity. Figure 3 depicts the major findings regarding the structure and physiological role of 
SULT1E1. 
 
Figure 3: Physiological role of SULT1E1 in the sulfoconjugation of estrogens. 
Endogenous or synthetic estrogens bind to either the catalytic or allosteric domains of the SULT1E1 dimer. 
Two molecules may bind independently. SULT1E1 catalyzes the transfer of a sulfate group from the universal 
donor 3ʹ- phosphoadenosine-5ʹ-phosphosulfate (PAPS) to the 3ʹ-hydroxy group of E2. Upon sulfonation, 
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estrogens become hydrosoluble and unable to bind to the estrogen receptor (ER) ⍺  nor β. Consequently, 
unlike the parent estrogens, the sulfonated estrogens cannot translocate to the nucleus and cause ER and 
estrogen response element (ERE) mediated regulation of target genes.  
 
SULT1E1-mediated sulfoconjugation and deactivation of estrogens is a reversible reaction 
because the hormonally inactive estrogen sulfates can be desulfonated and re-activated by STS. 
STS is responsible for catalyzing the hydrolysis of steroid sulfates and generating hydroxysteroids. 
This enzyme is present in several tissues, especially in the liver, where the metabolism of 
circulating steroid hormones mainly happens [64]. Therefore, SULT1E1-mediated 
sulfoconjugation and deactivation of estrogens is a reversible reaction, because the hormonally 
inactive estrogen sulfates can be desulfonated and re-activated by STS. In patients with chronic 
inflammatory liver diseases, inflammation-mediated activation of NF-kB in hepatocytes stimulates 
STS, and consequently the levels of circulating estrogens rise, which mitigates this inflammatory 
response [65]. Moreover, STS has been implicated in a sex-linked role in energy homeostasis, 
because transgenic overexpression of human STS in adipose tissue or liver of male and female 
mice resulted in different responses to high-fat diet (HFD)-induced obesity and type 2 diabetes 
mellitus (T2DM). In female mice, the inflammatory profile and metabolic functions were 
improved due to increased estrogenic activity whereas in male mice the metabolic response was 
worsened [66, 67]. 
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1.3.1 Transcriptional regulation of SULT1E1 by nuclear hormone receptors and its 
implications in drug-hormone interactions. 
The expression of SULT1E1 is subject to the transcriptional regulation by nuclear hormone 
receptors, a family of ligand-dependent transcriptional factors. The regulation of SULT1E1 by 
nuclear receptors provides a mechanism for the drug/hormone-hormone interactions that lead to 
compromised estrogen activities. Several classes of drugs may indirectly modulate SULT1E1 
activity. For instance, glucocorticoids, such as dexamethasone (Dex), have been shown to reduce 
estrogenic activity in vivo and in vitro by increasing the expression of SULT1E1. The induction of 
Sult1e1 and the resultant inhibition of estrogen activity by Dex were consistent with previous 
reports that glucocorticoids can inhibit estrogen responses [68-73]. Treatment with Dex attenuated 
the estrogen-induced uterine expression of insulin-like growth factor-I (IGF-I) [72].  DEX also 
blocked the stimulatory effect of estrogen on MCF-7 cell proliferation [71, 73]. Mechanistically, 
Dex interacts with the glucocorticoid receptor (GR), which acts as a transcriptional factor that 
promotes the upregulation of its transcriptional target, Sult1e1; consequently, Sult1e1 induction is 
responsible for dramatically reducing the levels of active estrogens [71]. Similarly, cholesterol-
derived oxysterols, or synthetic agonists such as GW3965, bind to the isoforms α and ß of the liver 
X receptor (LXR); this ligand-receptor complex, in turn, stimulates the transcription of hepatic 
Sult1e1, resulting in an increased estrogen sulfonation and decreased estrogen activity [74].  
The regulation of SULT1E1 by nuclear receptors can be both sex-specific and species-
specific. As an example of sex-specificity, in female mice, the constitutive androstane receptor 
(CAR) agonist, TCBOPOP, was shown to induce liver Sult1e1, whereas in male mice the induction 
was not observed [75]. As an example of species specificity, although the regulation of Sult1e1 by 
Lxr has been reported in mice, the same regulation is yet to be verified in humans. In addition to 
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the positive regulation, some nuclear receptors are associated with a decreased activity of Sult1e1. 
Retinoid-related orphan receptor alpha (RORα) is a negative regulator of Sult1e1 in hepatocytes, 
therefore, the effects of agonists, such as cholesterol- and lipid-sulfates, and antagonists of RORα 
can modulate the activity of this steroid enzyme [76]. Another nuclear receptor agonist that 
downregulates Sult1e1 is the antibiotic rifampicin, a known activator of the human pregnane X 
receptor (PXR). Rifampicin represses the transcription of Sult1e1 in hepatocytes via interaction 
with hepatocyte nuclear factor 4α (HNF4α) [77]. Recently, Wang and colleagues also showed that, 
in HepG2 cells, the farnesoid X receptor (FXR) agonists, 3-(2,6-Dichlorophenyl)-4-(3’-carboxy-
2-chlorostilben-4-yl), oxymethyl-5-isopropylisoxazole (GW4064) and chenodeoxycholic acid 
(CDCA), indirectly downregulated SULT1E1 via the prevention of peroxisome proliferator-
activated receptor-γ coactivator 1α (PGC1α) binding to HNF4α [78]. The role of nuclear receptors 
in Sult1e1 regulation is summarized in Figure 4. 
 
Figure 4: Regulation of SULT1E1 by nuclear receptors. 
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Normally, SULT1E1 has a low expression in some tissues, such as the liver. Upon the presence of a ligand (L), 
that can be either dexamethasone, GW3965, or TCPOBOP, the nuclear receptors GR, LXR, or CAR, 
respectively, can bind to the promoter region of the Sult1e1 gene and increase its expression in the liver. * 
indicates that the induction only occurs in livers of female mice. In contrast, retinoid-acid related orphan 
receptor alpha (RORα) suppresses the expression of Sult1e1 in the presence of its agonists Bexarotene (BEX). 
Similarly, upon the binding of its agonist rifampicin (RIF), pregnane X receptor (PXR) binds to the 
transcription factor hepatocyte nuclear factor 4α (HNF4α), which culminates with the downregulation of 
Sult1e1. Additionally, agonists for farnesoid X receptor (FXR), such as GW4064, prevent the binding of 
PGC1α to HNF4α, also leading to EST downregulation. 
 
1.3.2 Metabolism of estrogenic drugs by SULT1E1 
1.3.2.1 Estrogenic drugs that are SULT1E1 substrates 
Synthetic oral contraceptives are widely used among fertile women. Norethindrone (NET) 
and ethynylestradiol (EE) are the major active compounds in this medication group [79]. 
Cytochrome P450 (CYP) enzymes are responsible for the phase I metabolism of endo- and 
xenobiotics. CYP3A4 and CYP2C9, followed by CYP2C8, CYP2C19, and CYP3A5, are the major 
enzymes responsible for oxidizing EE into 2-hydroxy-EE, which accounts for more than 90% of 
all metabolites [79]. Sulfation at the 3-O group of 2-hydroxy-EE accounts for up to 60% of EE’s 
first-pass metabolism.   
The proportion of intestinal over hepatic SULTs effective in this metabolism is 
approximately 2:1 [80]. Inhibition analysis with the SULT1A1 inhibitor quercetin and the 
SULT1E1 inhibitor 2,6-dichloro p-nitrophenol (DCNP) showed that SULT1E1 is the SULT enzyme 
with the highest affinity for EE, with a Km value of 6.7 nM, being responsible for 75-80% of the 
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sulfoconjugation [61]. Moreover, the metabolism of EE may be altered when co-administered with 
agents that reduce its plasma levels, such as rifampicin [81], or agents that increase EE levels, such 
as acetaminophen, fluconazole, and ascorbic acid[82-84]. On the other hand, the acetylenic group 
of EE may act as an inhibitor of several CYP enzymes [85, 86], such as CYP2B1, CYP2B6, and 
CYP3A4 [87, 88]. Additionally, in the human intestinal mucosa, EE was shown to indirectly inhibit 
sulfation considerably, as in the case of the progestogen (progesterone) oral contraceptive 
desogestrel, whose sulfation was inhibited by up to 48% in the presence of EE [89]. 
Selective estrogen receptor modulators (SERMs) inhibit the effects of estrogens in breast 
tissue. Tamoxifen and Raloxifene (Evista®) are SERMs widely used to decrease the risk of 
developing hormone-receptor-positive breast cancer in susceptible postmenopausal women. 
Sulfation assays demonstrate that, at therapeutic levels, SULT1E1 has a high affinity for the 
tamoxifen metabolite, 4-hydroxytamoxifen (4-OHT), with a Km of 0.2 µM. Kinetic assays of 
raloxifene sulfation showed most SULT enzymes recognized this substrate; nonetheless, SULT1E1 
was the only SULT able to generate raloxifene monosulfates and disulfates. An affinity docking 
algorithm further demonstrated that in both rings of the molecule, the nucleophilic hydroxyls are 
placed in a crucial region for catalysis, predicting many possible interactions at two different 
positions. The analysis suggests this enzyme has a flexible active site that adjusts to accommodate 
reactive groups [90].   
Hormonal replacement therapy (HRT) is broadly used in postmenopausal women to reduce 
uncomfortable symptoms of menopause, including hot flashes, disturbed sleep, and vaginal 
dryness. Tibolone is a synthetic steroid used as an HRT agent to modulate bone loss, menopause 
symptoms, and libido, possibly due to a selective sulfatase inhibition. Once absorbed, Tibolone 
binds to ER, progesterone receptor (PG), and androgen receptor (AR), and is rapidly metabolized 
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into 3α-OH and 3ß-OH-tibolone, which can be further metabolized into ∆4-tibolone. Tibolone 
metabolism occurs mainly by steroid SULTs. SULT1E1 sulfoconjugates the 3-OH position of both 
3α-OH-tibolone and 3ß-OH-tibolone with a Km of 2.1 µM and 6.6 µM, respectively [90, 91]. 
Among estrogenic drugs, the clinical use of conjugated equine estrogens (CEEs) also 
involves SULT1E1 and the estrogen re-activating enzyme STS. As a natural formulation of 
extraction from pregnant mares’ urine, CEEs are one of the most prescribed estrogen production 
for postmenopausal HRT either alone or in combination with a progestin. CEEs are not a single 
estrogen but a complex containing 10 different estrogens in their sulfate esters, with estrone sulfate 
and equilin sulfate as the main constituents [92]. Since estrogen exerts its biological effect only in 
its unconjugated form, SULT1E1 and STS are reasonably believed to be involved in CEEs 
metabolic process.  
Similar to E2, which is also widely used in HRT, CEEs have been proven to benefit 
postmenopausal women, such as improvement of osteoporosis, with no increased risk of 
cardiovascular disease and invasive breast cancer [93, 94]. However, several randomized 
controlled trials (RCTs) have revealed significant declines in cognitive function as well as a higher 
incidence of probable dementia in patients receiving CEEs alone or in combination with 
medroxyprogesterone acetate (MPA) compared with placebo [95-97], whereas transdermal E2, in 
comparison to the placebo, was found played no effect on cognition [98]. Additionally, in 
postmenopausal women with an increased risk of Alzheimer’s disease, continued or discontinued 
use of estradiol could improve attention/working memory/processing speed (P =0.04) and verbal 
memory (P = 0.01) domains compared with continued or discontinued CEE use for 2years [99]. 
On the other hand, as the enzyme activating sulfated estrogen, STS also highly expresses in the 
brain. Evidence has shown that an STS inhibitor is related to the up-regulation of endogenous 
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dehydroepiandrosterone sulfate (DHEAS) which acts as γ-aminobutyric acidA receptor antagonists, 
resulting in a memory-enhancing effect [100]. Although these results might provide a possible link 
between estrogen sulfate and SULT1E1/STS in mental disorders, there is no solid evidence to 
support this view. The potential association and underlying mechanism need to be further 
evaluated. 
1.3.2.2 Chemicals that inhibit the SULT1E1 activity 
Polychlorinated biphenyls (PCBs) are environmental pollutants with estrogenic or anti-
estrogenic properties that have gained increasing attention due to their effects on animal 
reproduction and sexual development. Human exposure to PCBs has been associated with an 
increased incidence of testicular cancer and diminished semen quality and sperm counts [101]. It 
has been suggested that hydroxylated metabolites of PCBs (PCB-OHs) exert most of the hormonal 
properties of these compounds [102]. Kester et al investigated if PCB-OHs were inhibitors of E2 
metabolism and discovered that low concentrations of PCB-OHs (0.1 nM) were sufficient to bind 
to and inhibit human SULT1E1 with an affinity higher than the endogenous estrogens. Their results 
suggest that PCB-OHs may increase local estrogenic activity in reproduction-related organs by 
suppressing SULT1E1-mediated estrogen sulfation and deactivation. Moreover, the authors 
observed that a hydroxyl group in the para position of PCB-OHs with two nearby chloride 
substituents was required for interacting with the SULT1E11 enzyme and that the inhibitory effect 
was increased per the number of halogen groups in the molecule.  
Phenolic OH groups in PCB-OHs were also shown to be non-competitive inhibitors of E2 
sulfation since they do not bind to the active site, but the allosteric site of SULT1E1 [103]. 
Similarly, using recombinant human SULT enzymes, Miksits and colleagues demonstrated that 
although SULT1A1 was the major enzyme, SULT1E1 had a minor role in the sulfoconjugation of 
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3,4’,5-trihydroxy-trans-stilbene (Resveratrol) [104, 105]. This is a polyphenol chemical present in 
the herb Polygonum cuspidatum, that among many functions also has estrogenic activity. The 
substrate inhibition profiles of the resveratrol metabolites, trans-resveratrol-3-O-sulfate (M1), and 
trans-resveratrol-4’-O-sulfate (M2) on SULT1E1 had a Ki value of 3.37 µM and 13.1 µM, 
respectively [104]. 
Triclosan, also known as Irgasan, is another established SULT1E1 inhibitor. Triclosan is a 
chlorinated phenolic compound that was used as an anti-microbial agent in hand soap and other 
personal care agents [106-109].  Triclosan has been detected in human blood, urine, and breast 
milk [110, 111]. People who accidentally ingested 4 mg of Triclosan presented 22 to 47% of the 
unconjugated molecule in plasma [112]. Stoker et al. evaluated the effects of Triclosan in female 
Wistar rats. They found that in pubertal mice this agent resulted in a premature vaginal opening, 
whereas in weaning mice Triclosan changed the degree of reproduction development and increased 
uterine response to EE [113]. In sheep, Triclosan was reported as a potent inhibitor of placental 
Sult1e1 by competing with E2 molecules for the enzyme’s substrate-binding site with a competitive 
inhibitory constant (Kic) of 0.09nM[58]. Besides the competitive inhibition, Triclosan also 
displays an uncompetitive inhibition of the E2-Sult1e1 interaction, with an uncompetitive 
inhibitory constant (Ki) of approximately 5.2 nM. In the same study, another PCB, 4’OH-CB79, 
also demonstrated competitive E2- Sult1e1 inhibition with a Ki of 0.89 nM[58]. Table 4 
summarizes all Sult1e1 substrates and inhibitors and their enzyme binding affinity.  
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Table 4: Binding affinity of substrates and inhibitors of Estrogen Sulfotransferase (Sult1e1) 
within different species. 
COMPOUND APPROXIMATE 
AFFINITY (nM) 
SPECIE ROLE REFERENCE 
17ß-Estradiol (E2) 0.27  Mouse Substrate [57] 
Estrone (E1) 1.8  Sheep Substrate [58] 
Estrone (E1) 40  Human Inhibitor [61] 
Ethynylestradiol 6.7  Human Substrate [61] 
4-hydroxytamoxifen 200  Human Substrate [90] 
DHEA 850  Human Substrate [60] 
3α-OH-Tibolone 2,100  Human Substrate [91] 
3ß-OH-tibolone 6,600  Human Substrate [91] 
Tibolone 19,500  Human Substrate [91] 
4’OH-CB79 0.89  Sheep Competitive 
Inhibitor 
[58] 
Triclosan 0.09  Sheep Competitive 
Inhibitor 
[58] 
Triclosan 5.2  Sheep Uncompetitive 
Inhibitor 
[58] 
Trans-resveratrol-3-
O-sulfate (M1) 
3,370  Human Inhibitor [104] 
Trans-resveratrol-4’-
O-sulfate (M2) 
13,100  Human Inhibitor [104] 
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1.3.3 Disease effect on the expression and activity of SULT1E1  
1.3.3.1 SULT1E1 in human diseases 
In humans, postmenopausal women receiving HRT have a higher risk of presenting serious 
side effects like pulmonary embolism, stroke, coronary heart disease, and cancer [114-117]. 
Cancer-focused studies have shown that the activity of SULT1E1 has been correlated with a 
reduction in breast, endometrial, and ovarian cancer recurrence and improved survival [118-121], 
whereas SULT1E1-negative breast tumors may be associated with a poor prognosis due to a rise 
in in situ estrogens [42, 122]. These phenomena are in accordance with the finding that an 
increased sulfation of E2 has been linked to decreased proliferation rates of hormone-sensitive 
malignant cells [123]. Endometriosis is manifested by abnormal growth of endometrial tissue 
ectopically of the uterus. Biopsy specimens of women with endometriosis presented a diminished 
expression of SULT1E1 and an augmented expression of STS in accordance with the dependence 
of endometriosis on female sex hormone [124]. 
Variations in the activity of SULT1E1 are responsible for differences in inter-individual 
response to hormonal-related diseases. Expression of SULT1E11 in the human liver, although 
showing no sex-differences, presents significant variations between alcohol consumers, as well as 
among different individuals, where it can vary up to 25-fold. The causes behind such variations 
are not fully elucidated but it is believed they could happen as a result of SULT1E1 polymorphisms 
and exogenous administration of estrogens [125]. Three nonsynonymous SULT1E1 coding single 
nucleotide polymorphisms (cSNPs) have been characterized in COS-1 cells. Constructs containing 
the cSNPs evidenced a decline in SULT1E1 activity,  which suggest such polymorphisms may be 
partly responsible for the advancement of estrogenic diseases and metabolic alterations of 
estrogenic drugs [126].  
 25 
Using genomic DNA extracted from buccal samples, Rebbeck and collaborators conducted 
a population based case-control study that evidenced an association between the chance of 
developing endometrial cancer and the G → A polymorphism at position -64 (−64G>A; 
rs3736599) of SULT1E1’s promoter region [119]. Although only a few studies have been 
conducted so far to understand the origin of such variations, lack of sex-specific expression 
changes suggest the role of SULT1E1 in homeostasis may go beyond a simple estrogen 
inactivation. 
1.3.3.2 Sult1e1 in rodent disease models 
The genes encoding SULT1E1 are highly conserved in humans and mice, because the 
mouse Sult1e1 shares 77% homology in amino acids with the human enzyme [43]. As a result, 
various mouse models have been used to further understand the impact of diseases on this enzyme, 
and vice-versa. Noticeably, the use of Sult1e1 loss of function and gain of function models 
permitted the advancement of studies regarding the role of this enzyme in estrogen homeostasis 
and disease pathogenesis. 
1.3.3.3 Sult1e1 in estrogen homeostasis and reproduction 
In animals, experiments using female Sult1e1 null mice showed the importance of this 
enzyme as a regulator of estrogen levels, especially during pregnancy as the fetal loss was a 
common feature and the surviving offspring were smaller and had excessive levels of estrogens 
[127].  
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1.3.3.4 Sult1e1 in adipocyte differentiation 
The adipose tissue plays an important role in lipid storage, energy balance and insulin 
response; nonetheless, the mechanisms surrounding adipogenesis are not fully understood. We 
reported that Sult1e1 was highly expressed in 3T3-L1 pre-adipocytes and at the time of cellular 
differentiation to mature adipocytes this expression was decreased considerably. Furthermore, 
upon Sult1e1 overexpression in 3T3-L1 cells, adipocyte differentiation was diminished due to an 
ERK1/2 MAPK-dependent inhibition of insulin signaling, whereas Sult1e1 ablation in adipocytes 
conferred differentiation. The enzymatic activity of Sult1e1 was required for the inhibitory effect 
of Sult1e1 on adipogenesis, because an enzyme-dead Sult1e1 mutant failed to inhibit adipocyte 
differentiation. An in vivo investigation using transgenic female mice overexpressing Sult1e1 
specifically in adipose tissue further confirmed that the adipocytes’ diameters were reduced. 
Interestingly, physiological concentrations of E2 had little effect on 3T3-L1 differentiation. Their 
results suggest that Sult1e1 is a negative regulator of adipogenesis in an estrogen-independent 
manner. The authors used transient transfection and luciferase reporter gene assay to examine other 
candidate substrates for SULT1E1, such as thyroid hormones, testosterone, glucocorticoids, and 
peroxisome proliferator-activated receptor gamma (PPARγ) ligands, but none of them were shown 
to be metabolized by this enzyme [128]. As such, the SULT1E1 substrate(s) responsible for the 
effect of Sult1e1 on mouse adipocyte differentiation remain to be defined. 
Curiously, the effect of Sult1e1 in adipocyte differentiation is species specific. We 
conducted a study using pre-adipocytes isolated from obese and non-obese subjects, combined 
with Sult1e1 loss of function and gain of function manipulations. Our results showed that Sult1e1 
positively regulates adipogenesis via loss of estrogenic activity, and that the enzyme expression is 
 27 
positively correlated with the body mass index. Moreover, human adipogenesis was affected by 
estrogen treatment [48].   
1.3.3.5 Sult1e1 in metabolic disease 
Type 2 Diabetes Mellitus (T2DM) is a metabolic syndrome associated with insulin 
resistance. The diabetic mouse model (db/db) presents a liver induction of Sult1e1 [129].  We 
showed that the hepatic expression of Sult1e1 was also markedly induced in the ob/ob mice, 
another genetic model of obesity and type 2 diabetes. In determining the functional relevance of 
Sult1e1 and its regulation by metabolic disease, we showed that ablation of Sult1e1 in female ob/ob 
(termed obe) mice resulted in improved metabolic function due to a rise in hepatic estrogenic 
activity, as ovariectomy abolished the protection. Interestingly, the effect of Sult1e1 ablation on 
obesity and type 2 diabetes was sex-specific, because Sult1e1 ablation in male ob/ob mice 
worsened their phenotype, which was accounted for by the ß-cell loss due to the boosted 
macrophage infiltration and inflammation in the white adipose tissue (WAT) [130].  
We initially thought the loss of expression and induction of hepatic Sult1e1 in the male obe 
mice was responsible for the worsened metabolic function. In a follow-up study, we were surprised 
to find that transgenic reconstitution of Sult1e1 in the adipose tissue, but not in the liver, attenuated 
diabetic phenotype in obe males. Mechanistically, adipose reconstitution of Sult1e1 in obe mice 
resulted in reduced local and systemic inflammation, improved insulin sensitivity, and increased 
energy expenditure. At the molecular level, adipose induction of lipocalin-2 (Lcn2) in male obe 
mice with adipose reconstitution of Sult1e1 (oae mice) may have contributed to the inhibition of 
inflammation, because the level of Lcn2 was negatively associated with TNF-α expression, and 
treatment of differentiated adipocytes with Lcn2 antagonized TNF-α-responsive inhibition of 
insulin signaling. The metabolic benefit of adipose reconstitution of Sult1e1 was sex-specific, 
 28 
because adipose reconstitution of Sult1e1 in obe females had little effect. Interestingly, although 
reconstitution of Sult1e1 in obe males improved metabolic phenotype, these mice were not 
protected from ß cell mass loss. Their results suggest Sult1e1 is crucial for WAT homeostasis in 
an estrogen and ß cell-independent manner [131]. 
1.3.3.6 Sult1e1 in liver injury induced by sepsis and ischemia-reperfusion 
Sepsis is a major cause of mortality in the intensive care unit (ICU). Although sepsis and 
its associated inflammation are known to decrease the expression and activity of many drug-
metabolizing enzymes, we found that upon bacterial lipopolysaccharide (LPS) treatment or 
subjecting mice to the cecum ligation and puncture (CLP), the hepatic expression of Sult1e1 was 
highly upregulated via the activation of the NF-kB pathway. The mouse Sult1e1 gene was 
established as a NF-kB target gene. The sepsis-responsive induction of Sult1e1 was sufficient to 
compromise the estrogen activity. Interestingly, not only sepsis can induce Sult1e1- the expression 
and activity of Sult1e1 can impact the clinical outcome of sepsis. Specifically, we showed that 
Sult1e1 ablation or pharmacological inhibition of Sult1e1 by Triclosan sensitizes mice to sepsis-
induced death in an estrogen dependent manner. Mechanistically, Sult1e1 ablation attenuates 
sepsis-induced inflammatory responses due to compromised estrogen deactivation, leading to 
increased sepsis lethality. The reciprocal regulation of inflammation and Sult1e1 may represent a 
yet to be explored mechanism of endocrine regulation of inflammation, which has an impact on 
the clinical outcome of sepsis [49]. 
Liver ischemia-reperfusion injury (LIRI) is another liver injury condition that can regulate 
Sult1e1. Sult1e1 has also been studied in inflammation-based conditions. LIRI is caused by hepatic 
blood flow blockage or reduction and is a common feature after organ transplantation, abdominal 
surgeries, massive trauma, hemorrhagic- and cardiogenic shock. LIRI is directly associated with 
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oxidative stress and inflammation. We reported that LIRI induced Sult1e1 in the mouse liver, and 
that upon Sult1e1 ablation the female mice were protected from the injury in an estrogen dependent 
manner, whereas the male mice were further sensitized in an androgen-dependent manner. The 
LIRI responsive induction of Sult1e1 is dependent on the nuclear factor erythroid 2-related factor 
2 (Nrf2), but independent of the hypoxia-inducible factor 1 (HIF-1). Sult1e1 was established as a 
Nrf2 target gene [46].  
1.3.3.7 Sult1e1 in cystic fibrosis 
Cystic fibrosis (CF) is an autosomal recessive condition characterized by mutations in both 
copies of the cystic fibrosis transmembrane receptor (CFTR) and manifested by pulmonary 
abnormalities. However, loss of CFTR is often linked to distant organ injury. The liver is one of 
the organs affected, which accounts for the high mortality observed in children with CF [132, 133]. 
Additionally, animal models of CF, characterized by both CFTR-deficient and CFTR KO mice, 
do not present pulmonary disease but manifest CF-associated gastrointestinal and reproduction 
comorbidities, such as severe growth retardation and mediocre weight gains [134]. Furthermore, 
CF patients present growth shortfalls that are associated with a decline in IGF-1 plasma levels 
[135, 136]. Li and colleagues have demonstrated that hepatic Sult1e1 is induced in CFTR KO mice 
[137] and that in SULT1E1-transfected HepG2 cells, SULT1E1 played a role in inhibiting both 
growth hormone-mediated signal transducers and activators transcription 5b (STAT5b) 
phosphorylation and insulin-like growth factor-1 (IGF-1) synthesis in an estrogen-dependent 
aspect [123]. As a result of estrogenic decline, the expression of the hepatic detoxifying enzymes, 
glutathione S-transferase P1 and carbonic anhydrase, are also downregulated in CFTR mice [137]. 
In addition, Falany and colleagues showed that co-transfection of HepG2 hepatocytes with human 
MMNK-1 cholangiocytes transfected with CFTR siRNA resulted in SULT1E1 induction in an 
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LXR-dependent manner due to changes in cholesterol biosynthesis [138]. Therefore, SULT1E1 
induction in CF patients may be responsible for growth retardation and indicate a disrupted 
paracrine regulatory mechanism that may help elucidate the reasons behind CF-dependent liver 
damage. A general association between disease onset and SULT1E1 regulation is summarized in 
Table 5. 
Table 5: Disease onsets that were shown to regulate Estrogen Sulfotransferase (SULT1E1) 
expression within different species. 
DISEASE STATE EST REGULATION SPECIE REFERENCE 
Endometrial Cancer Downregulated Human [118] 
Ovarian Cancer Downregulated Human [120] 
Breast Cancer Downregulated Human [121] 
Endometriosis Downregulated Human [124] 
Metabolic disease Upregulated Mouse [130] 
Sepsis Upregulated Mouse [139] 
Ischemia-
reperfusion 
Upregulated Mouse [140] 
Cystic Fibrosis Upregulated Mouse [137] 
 
1.3.3.8 Sult1e1 in AKI 
Animal studies have suggested that estrogens may protect mice from AKI [141] [142, 143]. 
Epidemiology studies suggested that women below the age of menopause are believed to be 
protected due to the anti-inflammatory effects of estrogens [144-146] whereas the male sex can be 
an independent risk factor for AKI [18, 147-150]. It is unclear whether Sult1e1 plays a role in the 
pathogenesis of AKI and if so, whether the effect of Sult1e1 on AKI is sex hormone dependent. 
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1.4 Hypothesis and specific aims 
Acute kidney injury (AKI) is defined as an abrupt impairment of kidney function. The 
acute ischemic AKI model was established by clamping the pedicle vessels of both kidneys to 
block the blood flow for 30 minutes. Besides its effect on kidneys, AKI has been reported to affect 
many distal organs, including the liver. Studies suggest estrogens may protect mice from AKI and 
that women below the age of menopause are believed to be protected due to the anti-inflammatory 
effects of estrogens. Moreover, male sex can be an independent risk factor for AKI. SULT1E1 is 
the enzyme that exhibits the greatest affinity for estrogens, especially the 3-hydroxyl position of 
E2. Sult1e1 was the most highly induced gene in the livers of AKI mice, and this gene was also 
induced in the kidneys of male mice, but not female. 
Hypothesis: Estrogen sulfotransferase (Sult1e1/EST) exacerbates ischemic acute kidney 
injury due to inactivation of estrogens. 
Specific Aim 1: To abolish Sult1e1 expression in AKI mice and investigate estrogenic 
response. 
For the specific aim 1, eight-week old male and female Sult1e1 knockout (Sult1e1 KO) 
mice as well as WT mice of similar age treated with IP injections of corn oil or 10mg/kg or 
50mg/kg of triclosan were analyzed. These mice were challenged with AKI or the sham surgery, 
and were sacrificed 24 h after. Kidney injury markers, such as serum creatinine, blood urea 
nitrogen, kidney NGAL expression, PAS and TUNEL staining, and the inflammatory marker IL-
6 were significantly decreased in Sult1e1 KO mice and triclosan-treated WT. Therefore, they 
exhibited a marked protection from AKI.  
For a second part of this specific aim, male and female Sult1e1 KO that underwent 
gonadectomy at 4-5 weeks were also used. Ovariectomized or castrated Sult1e11 KO mice were 
 32 
also protected from AKI, as determined by the aforementioned markers, demonstrating the effects 
mediated by Sult1e1 ablation are androgen- and estrogen-independent.  
Specific Aim 2: To compare the importance of liver and kidney Sult1e1 for AKI 
development and investigate the injury mediator. 
Knowing hepatic Sult1e1 is induced by AKI, for the first part of specific aim 2, we wanted 
to determine whether the hepatic expression of Sult1e1 distantly contributed to the pathogenesis 
of AKI. For this purpose, we reconstituted the expression of Sult1e1 tissue-specifically to the liver 
by using the KOLE mice. In the male mice, restoration of liver Sult1e1 was sufficient to re-
sensitize KOLE mice to AKI, whereas female KOLE were still protected from the injury, 
indicating the importance of liver Sult1e1 for males and a sex-difference that does not rely on sex 
hormones. 
For the second part of specific aim 2, since the kidney protective effect of Sult1e1 ablation 
was sex hormone-independent, we went on to determine whether the metabolism of other 
endogenous substrates may have been responsible for kidney protection. In this effort, we 
performed Affymetrix microarray analysis comparing the transcriptomic profile in the kidneys of 
WT AKI and Sult1e1 KO AKI mice. Microarray showed altered expression of several genes 
involved in vitamin D metabolism and cell proliferation in the Sult1e1 KO AKI group, such as 
Cyp24a1 and Cyclin D1, which were confirmed at the mRNA and protein level. These results 
suggested that the increased VDR signaling may have contributed to the kidney protective effect 
of Sult1e1 ablation, despise SULT1E1 not recognizing active vitamin D, or calcitriol, as a substrate.  
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1.5  Dissertation outlines 
The contents of the dissertation include:  
Chapter I. Introduction is a concise description of AKI; and a literature review of how 
estrogen sulfotransferase mediates the metabolism of estrogenic drugs and how it interferes in the 
pathogenesis of diseases. It also includes overall research hypothesis, and specific aims. 
Chapter II. Methods with general research approaches.  
Chapter III. Sult1e1 in ischemic AKI mice is a complete research report that describes 
the experimental results of Aims 1 and 2, discussion and conclusion.  
Chapter V. Summary is a conclusive overview of the strategies currently used in the 
management of late AKI stages, as well as safety studies regarding triclosan, and future work. 
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2.0 Methods 
Animals. WT C57BL/6 mice were purchased from the Jackson laboratories (Bar Harbor, 
ME). The creations of Sult1e1 KO [151] and liver-specific Lap- SULT1E1/EST (LE) transgenic 
mice [139] were reported previously. The LE transgenic mice express the human SULT1E1/EST 
transgene in the liver under the control of the hepatocyte-specific liver-enriched activator protein 
(Lap) gene promoter. The KOLE mice, which are Sult1e1 KO mice with the liver-specific 
reconstitution of SULT1E1, were created by cross-breeding the Sult1e1 KO and LE transgenic 
mice as we have previously reported [152]. In the KOLE mice, the Sult1e1 KO allele and LE 
transgenic allele were independently genotyped by PCR. Mice were maintained in a temperature-
controlled animal facility at the University of Pittsburgh. The use of animals complied with the 
guidelines established by the Institutional Animal Care and Use Committee of the University of 
Pittsburgh. 
Ischemia-Reperfusion Model of AKI. To induce AKI, both kidneys were clamped to 
block blood flow for 30 minutes. After ischemia, clamps were released to start reperfusion, and 
mice were sacrificed after 1, 2, 6, 24, or 72 hours. Blood samples were collected by cardiac 
puncture. Kidneys and livers were harvested for analysis. The sham surgery is a midline incision. 
Histological Analysis. The kidney and liver tissues were fixed in 10% neutral buffered 
formalin for 24 hours and then dehydrated, embedded in paraffin, sectioned at 4 mm, and stained 
with periodic acid Schiff (PAS), and counterstained with hematoxylin. Immunostaining was 
performed on paraffin sections. Slides were incubated overnight with the primary anti- SULT1E1 
antibody (12522-1-AP) from Proteintech (Rosemont, IL), anti- CD3 antibody (MAB4841) from 
R&D Systems (Minneapolis, MN), anti-Cyp24a1 antibody (ab203308), anti-Ki67 antibody 
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(ab66155) from Abcam (Cambridge, MA), or anti-neutrophil gelatinase-associated lipocalin 
(NGAL) antibody (MAB1857) from R&D Systems. Antibodies were diluted to 1:100 (liver) or 
1:50 (kidney) and incubated in humid chambers overnight at 4°C. Specimens were then treated 
with fluorescence- or biotin-conjugated secondary antibodies. Terminal transferase dUTP nick-
end labeling (TUNEL) staining was performed by using the In Situ Cell Death Detection Kit from 
Roche (Mannheim, Germany).  
Serum Biochemical Analysis of Creatinine, BUN, ALT, IL-6, and 17ß-E2. Creatinine 
levels were measured with the QuantiChrom Creatinine Assay Kit from BioAssay System 
(Hayward, CA). BUN was measured by using the QuantiChrom Urea assay kit (Cat #DIUR-100) 
from BioAssay Systems (Hayward, CA). The ALT levels were analyzed with the Stanbio ALT kit 
from Laboratory (Boerne, TX). The concentrations of IL-6 were measured by an enzyme-linked 
immunosorbent assay kit from R&D Systems. Serum levels of 17ß-E2 were measured by the 
Center for Research in reproduction at the University of Virginia using the ELISA (Calbiotech) 
kit.  
Cell cultures. Primary hepatocytes were isolated from 12-week-old male WT mice by liver 
perfusion [153]. Hepatocytes were seeded onto type 1 collagen-coated dishes in William E 
medium containing 5% FBS until confluent. After 24 hours, the medium was replaced with 
William E medium supplemented with vehicle or IL-6 (70 ng/mL) for 24 hours before cell 
harvesting. Human kidney proximal tubular (HKC-8) cells were cultured in DMEM-F12 and 5% 
FBS until confluent. The cells were then treated with vehicle or IL-6 (35 ng/mL) for 24 hours 
before cell harvesting.  
RNA Isolation, Quantitative Real-Time PCR, Northern Blot, and Affymetrix 
Microarray Analysis. Total RNA was isolated using the TRIZOL reagent from Invitrogen 
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(Carlsbad, CA). Total RNA was treated with RNase-free DNase I, and the resultant DNA-free 
RNA was used to synthesize single-strand cDNA. Real-time PCR was performed on an ABI 7300 
Real-Time PCR System from Applied Biosystems (Foster City, CA). The primer sequences are 
listed in Table 6. Melting curve analysis was performed to determine the specificity of 
amplification. Gene expression was normalized to the expression of the control cyclophilin gene. 
Northern blot analysis using a 32P-labeled cDNA probe was performed as previously described 
[154]. Affymetrix microarray analysis was performed at the High Throughput Genome Center at 
the Department of Pathology, University of Pittsburgh. Microarray data were first quantile 
normalized across samples. The probe-level intensities were then mapped to gene-level expression. 
If multiple probes are mapped to the same gene, only the probe with largest inter quartile range 
will be kept. Then the top 200 up-regulated and 200 down-regulated genes were selected based on 
log2 fold change. These differentially expressed genes were used as input for Ingenuity Pathway 
Analysis (IPA)®, with significant pathways defined by FDR=5%.  
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Table 6: qRT-PCR primer sequences. 
Mouse genes Forward Reverse 
Car GGAGGACCAGATCTCCCTTC 
 
GTGGAGGATCGACTCCAAAA 
 
Cyp24a1 GAGGAAGAAGCCCTGACCTT 
 
TGCAGGGCTTGACTGATTTG 
 
Fgg GTGCTGGCTGTAAAGAGCTG 
 
TGGGCAGAAACTACCGAATCT 
 
Il-6 TCCTCTCTGCAAGAGACTTCCATCC 
 
GGGAAGGCCGTGGTTGTCACC 
 
Lxr GCCTCAATGCCTGATGTTTC 
 
CTGCATCTTGAGGTTCTGTCTTC 
 
Ngal AATGTCACCTCCATCCTGGT 
 
ATTTCCCAGAGTGAACTGGC 
 
Stat5a GCTCAGCGCCCACTTCA 
 
GACTCTGCACCACGCCTGT 
 
Sult1e1 GCCAAAGATGTCGCCGTTTC 
 
AACCATACGGAACTTGCCCT 
 
 
Transient Transfection and Luciferase Reporter Gene Assay. The pCMX-VDR, tk-
VDRE [155] and pCMX- SULT1E1 [140] constructs were described previously. HEK293T cells 
were transiently transfected with pCMX-VDR and tk-VDRE plasmids, with or without the co-
transfection of pCMX- SULT1E1 plasmid, using Lipofectamine 2000 from Invitrogen. pCMX-ß-
gal plasmid was added as an internal control to monitor the transfection efficiency. After 
transfection, cells were treated with vehicle or calcitriol (10 nM) for 24 hours. The luciferase 
activity was normalized to the ß-gal activity. 
Statistical Analysis. All data are expressed as the mean ± SD. Statistical analysis was 
performed using Student’s t-test or one-way analysis of variance where appropriate. Differences 
between groups were considered statistically significant at P < 0.05. Multiple comparisons were 
evaluated by one-way analysis of variance followed by Tukey’s multiple comparison tests.  
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3.0 Results 
3.1 AKI induces the hepatic expression of Sult1e1 in both male and female mice, but 
induces the kidney expression of Sult1e1 only in male mice 
The ischemic AKI model was established by clamping the kidney pedicle vessels of both 
kidneys to block the blood flow for 30 minutes. The AKI-induced kidney injury in male mice was 
confirmed at the biochemical, gene expression, and histological levels (Fig. 5). We used 
microarray to determine the effect of AKI on hepatic and kidney gene expression in mice. The 
microarray datasets have been submitted to the NIH Gene Expression Omnibus (GEO) under the 
GEO records GSE138995, GSE138996, and GSE138997. The microarray results showed that 
Sult1e1 was the most highly induced gene in the livers of AKI mice, and the induction of hepatic 
Sult1e1 by AKI in both male and female mice was verified by qRT-PCR (Fig. 6A) and Northern 
blotting (Fig. 6B). The AKI induction of hepatic Sult1e1 was also confirmed by 
immunofluorescence (Fig. 6C). A basal expression of Sult1e1 was also detected in the kidneys of 
both male and female mice, but interestingly, AKI induced kidney expression Sult1e1 in male 
mice, but not in female mice as shown by qRT-PCR (Fig. 6D) and immunofluorescence (Fig. 6E).  
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Figure 5: Establishment of the bilateral kidney ischemia reperfusion model of AKI. 
(A) Schematic representation of the ischemic AKI model. (B-F) WT male mice were subject to the 30-min 
ischemic AKI, and the mice were sacrificed 24 h after the surgery. Shown are serum levels of creatinine and 
BUN (B), kidney mRNA expression of NGAL (C), kidney histology (D, with asterisks indicating tubular 
damage), serum ALT level (E), and liver histology (F). n=7 for each group. Scale bars are 50 µm. Results are 
presented as the mean ± SD. ***, P < 0.001; ****, P < 0.0001, compared with the sham group. 
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Figure 6: AKI induces the hepatic expression of Sult1e1 in both male and female mice, but induces the kidney 
expression of Sult1e1 only in male mice. 
Mice were subject to the 30-min ischemic AKI or the sham surgery, and mice were sacrificed, and tissues 
were harvested 24 h after the surgery. (A-B) Hepatic mRNA expression of Sult1e1 in male and female mice as 
shown by qRT-PCR (A) （line is too long in Panel A） and Northern blot analysis (B). 28S RNA was 
included as the loading control in Northern blotting. (C) Immunofluorescence staining showed hepatic 
expression of Sult1e1 in male and female mice. (D and E) Kidney expression of Sult1e1 in male and female 
mice was evaluated by qRT-PCR (D) and immunofluorescence (E). n=7 for each group. Scale bars are 50 µm. 
Results are presented as the mean ± SD. *, P < 0.05; ***,  P < 0.001, compared to the Sham groups. 
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3.2 Inflammation is a potential mechanism for AKI responsive induction of Sult1e1 in the 
liver 
The Sult1e1 gene has been reported to be positively regulated by nuclear receptors 
constitutive androstane receptor (CAR) [75] and liver X receptor α (LXRα) [74]. The expression of 
Car was suppressed as we have previously reported [23], whereas the expression of Lxrα was not 
affected by AKI (Fig.7A), suggesting that the AKI-responsive induction of hepatic Sult1e1 was 
nuclear receptor independent. We have previously reported that the expression of Sult1e1 can be 
induced by inflammation in sepsis and the Sult1e1 gene is a transcriptional target of NF-kB [139]. 
Ischemic AKI is known to trigger local and systemic inflammatory responses [156], so we 
speculated that the AKI responsive inflammation and subsequent secretion of inflammatory 
cytokines into the circulation may have contributed to the hepatic induction of Sult1e1. Indeed, 
AKI induced kidney and hepatic expression of Il-6 (Fig. 7B), and increased the circulating level 
of Il-6 (Fig. 7C). Time course analysis showed that the induction of hepatic Il-6 and Il-1β preceded 
the induction of Sult1e1, in that the hepatic expression of Il-6 and Il-1β started increasing 1 h after 
AKI (Fig. 7D), whereas the expression of Sult1e1 did not increase until 6 h after AKI (Fig. 7E). 
The kidney infiltration of cluster of differentiation 3 (CD3)+ cells, a surface marker of T cells,  
was increased upon AKI, consistent with the inflammatory response of the kidney (Fig. 7F). In 
vitro, treatment with Il-6 induced the expression of SULT1E1 in primary hepatocytes (Fig. 7G) 
and in the human kidney proximal tubular (HKC-8) cells (Fig. 7H). Together, these results 
suggested that AKI may distantly induce the expression of Sult1e1 in the liver as a result of AKI-
responsive inflammation as summarized in Fig. 7I.  
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Figure 7: Inflammation is a potential mechanism for AKI responsive induction of Sult1e1 in the liver. 
(A-F) Mice are the same as described in Figure 1. Shown are hepatic mRNA expression of Car and Lxrα (A), 
hepatic and kidney mRNA expression of Il-6 (B), serum level of Il-6 measured by ELISA (C), time course of 
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hepatic expression of Il-6 and Il-1β (D) and Sult1e1 (E), and immunofluorescence of Sult1e1 and CD3 (F). (G 
and H) The expression of SULT1E1 in primary hepatocytes (G) and HKC-8 cells (H) treated with vehicle or 
Il-6. (I) Proposed model of Il-6-mediated distal regulation of hepatic Sult1e1 by AKI. Scale bars are 50 µm. 
Results are presented as the mean ± SD. *, P < 0.05; **, P < 0.01; ****, P < 0.0001, compared with the sham 
groups. 
3.3 Genetic ablation or pharmacological inhibition of Sult1e1 protects mice from AKI  
Male sex is an independent risk factor for AKI and it’s believed females are more resistant 
because of estrogens [144, 145, 157]. To determine the functional relevance of Sult1e1 and its 
regulation by AKI, in accordance to aim 1, we challenged eight-week old female Sult1e1 knockout 
(Sult1e1 KO) mice with AKI or the sham surgery, and the mice were sacrificed for analysis 24 h 
after. The Sult1e1 KO mice exhibited a marked protection from AKI, including the abolishment 
of AKI-responsive increase of serum level of creatinine and blood urea nitrogen (BUN) (Fig. 8A), 
attenuation of AKI-responsive induction of kidney injury marker gene neutrophil gelatinase 
associated lipocalin 2 (NGAL) (Fig. 8B), of kidney Il-6 (Fig. 8C), and kidney histology (Fig. 8D). 
The protective effect of Sult1e1 KO was not sex-specific, because the male Sult1e1 KO mice were 
also protected from AKI, as evidenced by serum creatinine (Fig. 9A) and BUN levels (Fig. 9B). 
NGAL was also decreased at both the mRNA (Fig. 9C) and protein (Fig. 9D) levels. At the 
histological level, the Sult1e1 KO mice subjected to AKI showed fewer tubular injury and less 
apoptosis, as shown by PAS staining and TUNEL assay, respectively (Fig. 9E). Moreover, the 
AKI-responsive kidney (Fig. 9F) and hepatic (Fig. 9G) induction of Il-6 was largely normalized 
in Sult1e1 KO mice, so was the circulating level of Il-6 (Fig. 9H). The kidney protective effect of 
Sult1e1 ablation remained obvious 72 h after the ischemic AKI, which was evidenced by lower 
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levels of serum creatinine and BUN (Fig. 10A), decreased kidney expression of NGAL (Fig. 10B), 
and reduced kidney tubular injury and apoptosis (Fig. 10C).  
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Figure 8: Knockout of Sult1e1 protects female mice from AKI. 
(A-D) WT and Sult1e1 KO female mice were subjected to the 30-min ischemic AKI, and the mice were 
sacrificed 24 h after the surgery. Shown are serum levels of creatinine and BUN (A) (any difference WT vs 
KO in sham?), kidney mRNA expression of NGAL (B) and Il-6 (C), and kidney histology (D, with asterisks 
indicating tubular damage). n=4 for each group. Scale bars are 50 µm. Results are presented as the mean ± 
SD. *P < 0.05; **, P < 0.01; ***, P < 0.001; the comparisons are labeled. 
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Figure 9: Knockout of Sult1e1 protects male mice from AKI. 
 47 
(A-H) WT and Sult1e1 KO males were subject to 30-min ischemic AKI or the sham surgery, and the mice 
were sacrificed 24 h after the surgery. Shown are serum level of creatinine (A), BUN (B), the mRNA (C) and 
protein (D) expression of kidney NGAL, histology as shown by PAS staining and TUNEL with the 
quantifications shown on the top right (E, with asterisks indicating tubular damage), kidney and hepatic 
mRNA expression of Il-6 (F-G), and serum level of Il-6 (H). n=3-6 for each group. Scale bars are 50 µm. 
Results are presented as the mean ± SD. *, P < 0.05; **, P < 0.01; ****, P < 0.0001; N.S., statistically not 
significant, with the comparisons labeled.  
 
 
Figure 10: Kidney protective effect of Sult1e1 ablation 72-hours post AKI. 
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(A-C) WT male mice were subjected to the 30-min ischemic AKI, and the mice were sacrificed 72 h after the 
surgery. Shown are serum levels of creatinine and BUN (A), kidney mRNA expression of NGAL (B), and 
kidney histology (C, with asterisks indicating tubular damage). n=4 for each group. Scale bars are 50 µm. 
Results are presented as the mean ± SD. *P < 0.05, compared with the WT AKI-72h groups. 
 
As also proposed in Aim 1, in an independent pharmacological model of Sult1e1 inhibition, 
WT mice were treated with triclosan, an efficient pharmacological inhibitor of Sult1e1[58], as 
outlined in Fig. 11A. Consistent with results from the Sult1e1 KO mice, treatment of female mice 
with 50 mg/kg dose of the Sult1e1 inhibitor triclosan was effective in attenuating AKI-responsive 
kidney injury in female mice (Fig. 11B-D). Treatment of male mice with triclosan at 10 mg/kg or 
50 mg/kg (Fig. 12A) also attenuated AKI, as shown by decreased serum creatinine and BUN levels 
(Fig. 12B), and kidney expression of NGAL (Fig. 12C). Triclosan-treated mice also presented 
improved histology (Fig. 12D), and decreased kidney and hepatic expression of Il-6 (Fig. 12E).  
 49 
 
Figure 11: Treatment with triclosan protects WT female mice from AKI. 
(A) Schematic representation of the triclosan (50 mg/kg) regimen. (B-D) Female mice were treated with three 
daily i.p. doses of triclosan or the vehicle corn oil before being subjected to the AKI surgery. Shown are 
serum levels of creatinine (B) and BUN (C), and the kidney histology (D, with asterisks indicating tubular 
damage). n=4 for each group. Scale bars are 50 µm. Results are presented as the mean ± SD. *P < 0.05; **, P 
< 0.01, compare to the corn oil AKI groups.  
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Figure 12: Pharmacological inhibition of Sult1e1 protects male mice from AKI. 
(A) Scheme of triclosan treatment. WT male mice received three doses of triclosan (10, or 50 mg/kg) or the 
vehicle corn oil before being subject to the 30-min ischemic AKI, and the mice were sacrificed 24 h after the 
surgery. (B-E) Shown are serum level of creatinine and BUN (B), kidney mRNA expression of NGAL (C), 
histology as shown by PAS staining and TUNEL with the quantifications shown on the bottom right (D, with 
asterisks indicating tubular damage), and kidney and hepatic mRNA expression of Il-6 (E). n=4-8 for each 
group. Scale bars are 50 µm. Results are presented as the mean ± SD. *, P < 0.05; **, P < 0.01, compared to 
the corn oil groups, or the comparisons are labeled. 
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3.4 The kidney protective effect of Sult1e1 ablation is estrogen- and androgen-independent 
Since the primary function of Sult1e1 is sulfonating and deactivating estrogens [62, 158], 
and administration of pharmacological doses of E2 after cardiac arrest protected male mice from 
AKI [141], we wanted to know whether the kidney protective effect of Sult1e1 ablation in male 
mice was estrogen dependent. To our surprise, the serum levels of E2 (Fig. 13A) were not 
significantly altered in male Sult1e1 KO AKI mice. The kidney expression of estrogen responsive 
gene Stat5 [159] was not affected either (data not shown). Additionally, the expression of 
aromatase, the enzyme that converts testosterones into estrogens, was undetectable in the liver or 
kidney (data not shown). As outlined in Aim 1, castration or ovariectomy were then performed on 
male or female Sult1e1 KO mice to determine whether the kidney protective effect of Sult1e1 
ablation was androgen and estrogen dependent, respectively. In this experiment, castration or 
ovariectomy was performed on Sult1e1 KO mice four weeks prior to the AKI surgery as outlined 
in Fig. 13B. Both castrated Sult1e1 KO males and ovariectomized Sult1e1 KO females remained 
protected from AKI as their sham surgery counterparts, as shown by serum levels of creatinine, 
BUN, and histology (Fig. 13C-F). The effectiveness of the ovariectomy surgery was confirmed 
by decreased uterine weight as percentages of the body weight in ovariectomized mice (Fig. 13G). 
These results suggested that the kidney protective effect of Sult1e1 ablation was sex hormone-
independent.  
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Figure 13: The kidney protective effect of Sult1e1 ablation is estrogen- and androgen-independent. 
(A) Mice are the same as described in Figure 3A. Shown are the serum level of E2. (B) Scheme of castration or 
ovariectomy followed by kidney ischemic AKI. (C and D) Intact Sult1e1 KO male mice or castrated Sult1e1 
KO males were subjected to Sham surgery or AKI surgery. Shown are serum levels of creatinine and BUN 
(C), and kidney histology as evaluated by PAS and TUNEL staining with their quantifications shown on the 
right (D, with asterisks indicating tubular damage). (E and F) Intact Sult1e1 KO female mice or 
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ovariectomized Sult1e1 KO females were subjected to Sham surgery or AKI surgery. Shown are serum levels 
of creatinine and BUN (E), and kidney histology as evaluated by PAS and TUNEL staining with their 
quantifications shown on the right (F, with asterisks indicating tubular damage). (G) Uterine weight as 
percentages of the body weight in female mice subjected Sham surgery or ovariectomy. n=4-6 for each group. 
Scale bars are 50 µm. Results are presented as the mean ± SD. 
3.5 Hepatic Sult1e1 is required for AKI injury in male, but not in female mice  
Knowing hepatic Sult1e1 is induced by AKI, we wanted to determine whether the hepatic 
expression of Sult1e1 distantly contributed to the pathogenesis of AKI. For this purpose, we 
reconstituted the expression of SULT1E1 tissue specifically to the liver by using the KOLE mice. 
KOLE mice were generated by cross-breeding the Sult1e1 KO mice with the Lap- SULT1E1/EST 
(LE) transgenic mice that express the human SULT1E1 transgene exclusively in the liver under 
the control of the liver-enriched activator protein (Lap) gene promoter [139] as outlined in Fig. 
14A. The KOLE mice overexpress Sult1e1 in the liver. Upon IRI, expression in the livers of male 
mice are further increase whereas in female the expression remains similar as Sham-operated 
female mice (Fig. 14B). Despite the liver expression, KOLE mice resemble a Sult1e1 KO 
background in other organs, including the kidney, which was verified by qRT-PCR (Fig. 14C). In 
the male mice, restoration of liver Sult1e1 was sufficient to re-sensitize KOLE mice to AKI, as 
shown by serum levels of creatinine and BUN (Fig. 14D), kidney mRNA expression of NGAL 
(Fig. 14E) and IL-6 (Fig. 14F), and histology (Fig. 14G). These results suggested that hepatic 
Sult1e1 is required for male mouse’s sensitivity to AKI. Interestingly, the effect of hepatic 
reconstitution of Sult1e1 on AKI was sex specific, because the female KOLE mice remained 
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efficiently protected from AKI, as shown by serum levels of creatinine and BUN (Fig. 14H) and 
histology (Fig. 14I).  
 
Figure 14: Hepatic Sult1e1 is required for AKI injury in male, but not in female mice. 
(A) Schematic representation of the KOLE mice that were created by breeding the liver specific Lap-
SULT1E1/EST (LE) transgene into the Sult1e1 KO background. (B) Reconstitution of SULT1E1 in the liver 
and (C) lack of reconstitution in the kidney was confirmed. (D-G) Male mice of indicated genotypes were 
subjected to the 30-min ischemic AKI, and the mice were sacrificed 24 h after the surgery. Shown are serum 
levels of creatinine and BUN (D), kidney mRNA expression of NGAL (E) and Il-6 (F), and kidney histology as 
shown by PAS staining and TUNEL with their quantifications shown on the right (G), with asterisks 
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indicating tubular damage). (H and I) Experiments were the same as described in (D-G) except that female 
mice were used. Shown are serum levels of creatinine and BUN (H) and kidney histology as shown by PAS 
staining and TUNEL with their quantifications shown on the right (I, with asterisks indicating tubular 
damage). n=6 for each group. Scale bars are 50 µm Results are presented as the mean ± SD. *P < 0.05, **, P < 
0.01; ***, P < 0.001; ****, P < 0.0001; N.S., statistically not significant, with the comparisons labeled. 
3.6 The protective effect of Sult1e1 ablation is associated with kidney regulation of vitamin 
D metabolizing and cell cycle genes 
Since the kidney protective effect of Sult1e1 ablation was sex hormone-independent, we 
went on to determine whether the metabolism of other endogenous substrates may have been 
responsible for kidney protection. In this effort, we performed Affymetrix microarray analysis 
comparing the transcriptomic profile in the kidneys of WT AKI and Sult1e1 KO AKI mice. 
Microarray showed altered expression of several genes involved in vitamin D metabolism and cell 
proliferation in the Sult1e1 KO AKI group (Fig. 15).  
The inductions of Cyp24a1 and Ccnd1 and suppression of Fgg were verified by qRT-PCR 
(Fig. 15A). Cyp24a1, which encodes a vitamin D metabolizing enzyme, is a known vitamin D 
receptor (VDR) target gene [160]. The expression of Ccnd1, which encodes Cyclin D1, has been 
reported upregulated at early rises of vitamin D [161] and may promote cell proliferation [162]. 
Fgg, which encodes fibrinogen, has been shown to have an inverse correlation with vitamin D 
levels [163]. This gene expression profile suggested that the VDR signaling was enhanced in the 
kidneys of Sult1e1 KO mice upon AKI. Administration of the active form of vitamin D calcitriol 
has been shown to improve several animal models of AKI [164, 165], and calcitriol is currently in 
clinical trials for the treatment of AKI [166]. These results suggested that the increased VDR 
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signaling may have contributed to the kidney protective effect of Sult1e1 ablation. The induction 
of Cyp24a1 and Cyclin D1 in Sult1e1 KO AKI kidneys and the loss of these inductions in KOLE 
AKI kidneys were confirmed by immunofluorescence (Fig. 15B and 15C), which correlated to 
the AKI protection and re-sensitization in these two genotypes, respectively. The increased kidney 
expression of Cyclin D1 was also verified by Western blotting (Fig. 15D). We speculate that the 
increased VDR signaling and the induction of Cyclin D1 may have contributed to the post-AKI 
kidney repair. Indeed, the kidney immunostaining of Ki67, a cell proliferation marker, was 
increased in Sult1e1 KO AKI kidney and this effect was attenuated in KOLE AKI kidney (Fig. 
15E). Our luciferase reporter gene assay results showed that overexpression of SULT1E1 did not 
affect the activity of calcitriol in inducing the VDR responsive reporter activity (Fig. 15F), 
suggesting that calcitriol is not a direct substrate of SULT1E1.  
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Figure 15: The protective effect of Sult1e1 ablation is associated with kidney regulation of vitamin D 
metabolizing and cell cycle genes. 
(A) Kidney mRNA expression of Cyp24a1, Ccnd1, and Fgg in WT and Sult1e1 KO mice subjected to 30-min 
ischemic AKI. (B and C) The kidney expression of Cyp24a1 (B) and Cyclin D1 (C) in WT, Sult1e1 KO, and 
KOLE mice subjected to 30-min ischemic AKI was shown by immunofluorescence. (D) The kidney expression 
of Cyclin D1 protein in WT and Sult1e1 KO mice subjected to 30-min ischemic AKI was shown by Western 
blotting with the signal quantifications labeled. (E) Immunostaining of Ki67 in the same groups, with 
arrowheads indicating positive staining. (F) 293T cells were transfected with a VDR reporter gene tk-VDRE 
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in the presence of the co-transfection of VDR plasmid and SULT1E1 plasmid alone or in combination. 
Transfected cells were treated with vehicle (ethanol) or Calcitriol (10 µM) for 24 h before cell lysis and 
luciferase assay. n=3-8 per group. Scale bars are 50 µm. Results are presented as the mean ± SD. **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001, compared to WT AKI (A), or the comparisons are labeled (F). 
3.7 Discussion 
The sex-specific effect of Sult1e1 on AKI is interesting. First, the regulation of Sult1e1 by 
AKI is sex-specific. AKI induced the hepatic expression of Sult1e1 in both male and female mice. 
However, the kidney induction of Sult1e1 by AKI only occurred in males, but not in females. 
Interestingly, the effect of Sult1e1 ablation and reconstitution was also sex-specific. Although both 
male and female Sult1e1 KO mice were protected from AKI, the reconstitution of Sult1e1 in the 
liver of male KOLE mice abolished the protective effect, whereas the female KOLE mice remained 
protected from AKI. Sex-specific effects of Sult1e1 ablation and/or reconstitution were also 
observed in our previous studies in the context of metabolic disease. We reported that Sult1e1 
ablation protected female ob/ob mice from obesity and type II diabetes, but sensitized male ob/ob 
mice to metabolic syndrome [130]. When the expression of Sult1e1 was reconstituted in the 
adipose tissue of Sult1e1 deficient ob/ob (obe) mice, the reconstitution effect was sex-specific, 
because the adipose reconstitution of Sult1e1 improved the metabolic function of male obe mice, 
but had little effect on the female obe mice [131, 167]. Interestingly, in both AKI and metabolic 
disease, the effect of Sult1e1 reconstitution was uniformly obvious in males, but not in female 
mice. The male-specific effect of adipose reconstitution of Sult1e1 was explained to be due to the 
high basal expression of Sult1e1 in the adipose tissue of male mice [131]. The basal expression of 
Sult1e1 in the liver is low in both sexes, so the mechanism underlying the male-specific effect of 
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the liver constitution of Sult1e1 on AKI remains to be understood. The sex-specific effect of 
Sult1e1 ablation was also observed in a mouse model of liver ischemia-reperfusion induced liver 
injury in that Sult1e1 ablation conferred protection to female mice, whereas the male mice were 
further sensitized [140]. The effect of Sult1e1 reconstitution on ischemia and reperfusion-induced 
liver injury remains to be tested. 
The tissue-specific effect of Sult1e1 on AKI is equally interesting. In male mice, although 
the AKI responsive induction of Sult1e1 was observed in both the liver and kidney, our results 
suggested that loss of Sult1e1 in the liver, but not in the kidney, was responsible for the 
renoprotection because reconstitution of Sult1e1 in the liver was sufficient to abolish the 
protection. Immunostaining of KOLE samples suggested a sex-difference in Sult1e1 expression 
upon IRI. This may have reflected on a lack of AKI effect in female KOLE mice. The role of basal 
and AKI inducible expression of kidney Sult1e1 in AKI-induced kidney injury in male mice 
remains to be defined. In female mice, although the loss of Sult1e1 in the liver was not responsible 
for the protection because the liver reconstitution of Sult1e1 had little effect, we cannot conclude 
that the loss of Sult1e1 in the kidney accounted for the renoprotection. It will be interesting to 
know whether the reconstitution of Sult1e1 in the kidney of female Sult1e1 KO mice will affect 
the protective effect of Sult1e1 ablation.  
The tissue-specific effect of Sult1e1 was also observed in our previous study in the ob/ob 
mice. The ob/ob mice exhibited liver-specific up-regulation of Sult1e1 [130]. Sult1e1 ablation in 
ob/ob (obe) males worsened the metabolic phenotype [130]. Interestingly, the transgenic 
reconstitution of Sult1e1 in the adipose tissue of male obe mice attenuated the metabolic 
phenotypes, including decreased local and systemic inflammation, improved insulin sensitivity, 
and increased energy expenditure [131, 167]. In contrast, the reconstitution of Sult1e1 in the liver 
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failed to improve the metabolic function of obe males [131]. These results suggested that although 
the hepatic Sult1e1 is markedly induced in ob/ob mice, it was not the loss of hepatic expression 
and induction of Sult1e1 that was responsible for the worsened metabolic function in obe males. 
Another interesting finding of this study is the estrogen and androgen independence of the 
AKI protective effect of Sult1e1 ablation because the protective effect was intact in Sult1e1 KO 
mice subject to ovariectomy or castration. The estrogen independence was a surprise, considering 
that a primary function of Sult1e1 is to regulate estrogen homeostasis, and estrogens have been 
suggested to be AKI protective in animals [141-143] and humans [18, 149]. Indeed, our previous 
study showed that the metabolic benefit of Sult1e1 ablation in female ob/ob mice was estrogen-
dependent, because the metabolic benefit was abolished upon ovariectomy [130]. The protective 
effect of Sult1e1 ablation on ischemia-reperfusion induced liver injury in female mice was also 
estrogen-dependent [140]. The androgen independence was also a surprise because prior studies 
suggested that castration ameliorates AKI, whereas testosterone administration worsens it [143]. 
In addition, the sensitizing effect of Sult1e1 ablation on ischemia-reperfusion induced liver injury 
in male mice was also androgen-dependent, because the sensitization was abolished upon 
castration [140]. It remains to be understood why the sex hormone dependence of the Sult1e1 effect 
varies among disease models. Nevertheless, the sex hormone independence of the AKI protective 
effect of Sult1e1 ablation suggested that Sult1e1 substrates other than estrogens might have been 
responsible for the Sult1e1 effect on AKI.  
Our gene profiling analysis suggested that increased vitamin D signaling may have 
contributed to the kidney protective effect of Sult1e1 ablation, because kidney expression of 
several VDR responsive genes, such as Cyp24a1, Ccnd1, and Fgg, was affected in Sult1e1 KO 
mice upon the AKI challenge. The enhanced VDR signaling may have explained the protective 
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phenotype because the administration of calcitriol has been shown to improve several animal 
models of AKI [164, 165], and calcitriol is currently in clinical trials for the treatment of AKI 
[166]. Furthermore, calcitriol and VDR signaling have been reported to promote cell proliferation, 
especially in cancerous and damaged cells [168].  As such, increased VDR signaling may have 
promoted cellular recovery and tissue repair after AKI, a notion supported by our observations of 
increased Ki67 and Cyclin D1 expression in AKI Sult1e1 KO mice. Calcitriol is also known for its 
anti-inflammatory activity [169], which could also have contributed to the renoprotection. Since 
we showed calcitriol is not a Sult1e1 substrate, the mechanism by which Sult1e1 ablation or 
inhibition increases VDR signaling remains to be understood. We recognize that both VDR 
activation and cyclin D1 induction in AKI Sult1e1 KO mice were associations. Future studies are 
necessary to determine whether these two events are required for the AKI protective effect of 
Sult1e1 ablation.  
Among the limitations, although we have identified interesting crosstalk between the liver 
and kidney, and showed clearly the loss of hepatic Sult1e1 was responsible for the AKI protective 
effect of Sult1e1 ablation, future studies are necessary to identify the mediators released from the 
liver that affect0 the kidney injury. Our microarray IPA analysis showed the kidneys of Sult1e1 
KO AKI mice had the highest positive z-score for the ataxia telangiectasia mutated (ATM) 
pathway (Fig. 16). A positive z-score indicates this pathway was activated. The ATM pathway is 
activated in the presence of DNA damage and stimulates DNA repair, DNA recombination, and 
cell-cycle control [170, 171]. Checkpoint kinase 2 (Chk2), the main effector of ATM kinase, is in 
charge of cell cycle regulation and also controls calcitriol formation [172]. Future studies are 
necessary to determine whether the ATM signaling could be a possible mediator for the 
renoprotection. The sex-specific effect of the hepatic reconstitution of Sult1e1 on Sult1e1 KO AKI 
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mice also remains to be better understood. IPA analysis of our microarray results suggest that the 
livers of WT female, but not male mice had a positive z-score for the vitamin D receptor/retinoid 
X receptor (VDR/RXR) pathway (Fig. 17 and 18), but its significance in female sensitivity to AKI 
remains to be defined.  
 
 
Figure 16: Ingenuity pathway analysis (IPA) of microarray results. 
Shown are z-scores and false discovery rate (FDR) of male kidney (KO AKI vs WT AKI). Several up-
regulated (orange arrows) and down-regulated (blue arrows) pathways are highlighted. 
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Figure 17: Ingenuity pathway analysis (IPA) of microarray results in male mice. 
Shown are z-scores and false discovery rate (FDR) of male liver (WT AKI vs WT Sham). Several up-
regulated (orange arrows) and down-regulated (blue arrows) pathways are highlighted. 
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Figure 18: Ingenuity pathway analysis (IPA) of microarray results in female mice. 
Shown are z-scores and false discovery rate (FDR) of female liver (WT AKI vs WT Sham). Several up-
regulated (orange arrows) and down-regulated (blue arrows) pathways are highlighted. 
 
In summary, we have uncovered a tissue- and sex-specific role of Sult1e1 in kidney 
ischemic AKI. The hepatic expression of Sult1e1 is required for an animal’s sensitivity to ischemic 
AKI in males. Pharmacological inhibition of Sult1e1 may represent a novel approach for the 
clinical management of AKI.  
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4.0 Summary 
4.1 Final considerations 
SULT1E1 has long been appreciated as a phase II metabolizing enzyme whose primary 
function is to sulfonate and deactivate estrogens, so SULT1E1 is implicated in the metabolism of 
estrogenic drugs, including drugs used in oral contraceptives and hormone replacement therapy 
(HRT).  
In several estrogen-dependent carcinomas, cancer cells activate mechanisms to decrease 
the expression of the deactivating enzyme SULT1E1 and increase the expression of the re-
activating enzyme, providing a mechanism for the initiation and progression of estrogen-
dependent cancers. Furthermore, patients with polymorphisms that lead to enzyme inactivation 
have a correlation with a worse prognosis.   
However, the physiological function of SULT1E1 remains to be fully elucidated yet, as 
several studies have suggested both estrogen-dependent and -independent roles of this enzyme in 
physiology and pathophysiology. Early studies based on the use of Sult1e1 null mice suggested a 
role of Sult1e1 in reproduction. In the past 10 years, results from the Xie laboratory and other 
groups have pointed to the functions of this enzyme beyond reproduction. The expression of 
Sult1e1 can be regulated by nuclear receptors and diseases. Sult1e1 is implicated in adipogenesis 
and in several mouse models of inflammation-driven conditions such as sepsis, diabetes mellitus, 
cystic fibrosis, and ischemia-induced injuries, like ischemic AKI.  
AKI therapy solely involves the management of its complications or the prevention of AKI 
causative factors. This dissertation shows the important role of Sult1e1 in the development of AKI 
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in mice. The high incidence of this disorder worldwide calls our attention to the necessity of a 
strict therapy that may reverse the injured kidney state or prevent it from reaching more serious 
stages. The most successful strategies currently used in the clinic for patients that develop late 
stages are RRT, and the last resort is kidney transplantation. However, these strategies are 
associated with risks, high cost, organ availability, and lack of any long-term benefits. 
4.2 Dissertation highlights 
This dissertation features the potential use of Sult1e1 inhibitors, such as triclosan, as an 
AKI preventive agent in mice. Since the 1960s, triclosan has been widely used topically as a broad-
spectrum antimicrobial agent found in a myriad of household products, such as toothpaste, soaps, 
deodorants, and lotions [106-109]. This molecule is also known for its anti-inflammatory potency, 
as it is believed it inhibits prostaglandin formation [173, 174]. The safety of oral administration of 
triclosan has also been evaluated previously [106]. The lethal dose (LD50) of oral triclosan in adult 
mice, dogs, and rats varies from 3,750mg/kg to more than 5,000mg/kg [175]. Although the 
intravenous toxicity can be seen in doses above 30mg/kg, regarding intraperitoneal injection this 
lethality is only reached in doses approximate to 1,090 mg/kg [176]. Moreover, male and female 
Sprague Dawley rats fed with 1000 parts per million (ppm) triclosan for a period of two years did 
not present liver toxicity nor any type of organ damage. This treatment did not affect reproduction 
and offspring either. Finally, human safety studies demonstrated that people exposed to toothpaste 
or mouth rinses containing 0.06% to 0.6% of triclosan within a period of 12 weeks had no adverse 
effects [175]. In our study, male and female C57bl/6 mice were treated with intraperitoneal 
injections of triclosan, with doses ranging from 10mg/kg to 50mg/kg daily for a total of three 
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consecutive days prior to bilateral kidney ischemia-reperfusion. This dose regimen was sufficient 
to protect mice from AKI and was greatly below the maximum tolerated dose in this species. 
Ablation or Inhibition of Sult1e1 protected mice from ischemic AKI. During its initial 
phase, IRI stimulates endothelial cell disruption and the release of proinflammatory mediators 
from endothelium and tubule cells, such as IL-6. Our results demonstrate that protected mice 
presented low levels of IL-6. This could be due to increased resistance to IRI and consequently 
decreased endothelial damage. Another possible explanation is that Sult1e1 played a direct impact 
on controlling the release of IL-6. Xu et al (2013) demonstrated that HUVEC cells treated with 
SULT1E1 siRNA had downregulation of IL6 expression. Those authors concluded that SULT1E1 
knock-down in these endothelial cells suppressed inflammation and lipid metabolism via PPARγ 
expression, in an estrogen-dependent and -independent manner [177]. Similarly, we demonstrated 
that the protection conferred to our Sult1e1 KO and Triclosan-treated WT was estrogen-
independent. However, no meaningful changes were found in PPARγ regulation in our study, 
suggesting that loss of SULT1E1 may suppress inflammation through different mechanisms.  
The species-specificity of the SULT1E1 functions is very challenging. It remains to be 
determined whether many of the disease effects on Sult1e1, including AKI, can be recapitulated 
in humans, an area that warrants more studies.  
4.3 Future directions 
This dissertation demonstrates that augmented Sult1e1 possibly decreases vitamin D 
signaling and consequently minimizes the repairing mechanism at the tubule cells. Our gene 
profiling analysis suggested that increased vitamin D signaling in Sult1e1 KO may have 
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contributed to the kidney protective effect. Administration of calcitriol has previously shown to 
improve several animal models of AKI [164, 165], and calcitriol is currently in clinical trials for 
the treatment of AKI [166]. Furthermore, calcitriol and VDR signaling have been reported to 
promote cell proliferation, especially in cancerous and damaged cells [168].  As such, increased 
VDR signaling may have promoted cellular recovery and tissue repair after AKI, a notion 
supported by our observations of increased Ki67 and Cyclin D1 expression in AKI Sult1e1 KO 
mice. Calcitriol is also known for its anti-inflammatory activity [169], which could also have 
contributed to kidney protection.  
There are still many gaps in this study. The real substrate that mediates AKI has not been 
found yet. Also, since we showed calcitriol is not a SULT1E1 substrate, the mechanism by which 
Sult1e1 ablation or inhibition increases VDR signaling remains to be understood. It’s also possible 
that other vitamin D metabolites or moieties, such as the calcitriol precursor, namely 25(OH)-
cholecalciferol (calcidiol) –which is activated in the liver by Cyp2r1 and has a longer half-life–, 
may be mediating this protective effect. Moreover, we recognize that both VDR activation and 
cyclin D1 induction in AKI Sult1e1 KO mice were associations. Future studies are necessary to 
determine whether these two events are indeed required for the AKI protective effect of Sult1e1 
ablation. VDR KO mice undergoing kidney ischemia-reperfusion could be used as a model to 
analyze the association of this receptor with cyclin D1 activity in the context of AKI.  
It is paramount to investigate molecules in the ATM signaling pathway that are vitamin D 
responsive. RNA-sequencing, which is more robust and sensitive than microarray, could be used 
to analyze genes regulated in the livers of Sult1e1 KO mice, in comparison to results obtained from 
their kidneys, as the mediator is probably being produced in the liver and migrating to the kidneys.  
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The bidirectional relationship between Sult1e1 expression and AKI must also be addressed. 
Hepatic Sult1e1 is induced in db/db mice in comparison to control, suggesting diabetes, 
hyperlipidemia, and obesity regulate SULT1E1 expression [129]. In human vascular smooth 
muscle cells, incubation with IL-1ß leads to an upregulation of SULT1E1. Moreover, severe 
atherosclerotic aorta samples from women had enhanced SULT1E1 expression in comparison to 
mild atherosclerotic samples [178]. Although IL-1ß was significantly increased in our model at an 
early time-point, the acute phase mediator IL-6 was the only pro-inflammatory molecule that 
increased in both liver and kidney at the 24h time-point. Hence, IL6 is likely responsible for 
inducing Sult1e1 in the kidneys and livers – likely in both Kupffer cells and hepatocytes – of AKI 
mice. However, it is still not clear by what mechanism IL6, or other inflammatory molecules, 
stimulate Sult1e1 expression in the liver, kidneys, and possibly other organs. Activation of IL6-
related pathways, such as the signal transducer and activator of transcription 3 (STAT3), should be 
investigated. Moreover, ROS can also regulate SULT1E1 expression, as they may either induce 
the expression of this enzyme via Nrf2 [179] or inactivate it via oxidized glutathione [180]. Trans-
signaling IL6 has also shown to work synergistically with ROS in AKI [181]. Therefore, a ROS 
inhibitor and a STAT3 inhibitor could be administered in different groups of mice prior to IRI to 
observe the real inflammatory pathway responsible for AKI induction.  
Likewise, the mechanism by which liver Sult1e1 is crucial for AKI development in males, 
and why this cannot be observed in females, should also be addressed. Loss of liver Sult1e1 
resulted in a low inflammatory response in males whereas, in females, other organs may have 
contributed to this effect.  
Intraperitoneal administration of triclosan daily for three consecutive days was sufficient 
to protect mice from AKI, and although the compound is overall safe, limitations to its use can 
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also be encountered. Triclosan may deplete the placenta’s ability to provide estrogen to the fetus, 
culminating with poor fetal growth and development [58] and also spontaneous abortion [182]. 
Furthermore, Triclosan has been detected in human blood, urine, and breast milk [110, 111]. 
People who accidentally ingested 4 mg of Triclosan presented 22 to 47% of the unconjugated 
molecule in plasma. In pubertal female Wistar rats, this agent resulted in a premature vaginal 
opening, whereas in weaning mice triclosan changed the degree of reproduction development and 
increased uterine response to EE [113]. Local triclosan administration has been previously 
suggested to treat infections and prevent systemic absorption [183]. Similarly, in AKI, local 
triclosan administration would be needed to prevent concerning effects in other organs, as 
SULT1E1 presents tissue-specific effects. 
This work also demonstrates the ischemic AKI protection effect conferred by Sult1e1 
ablation is male and female hormone-independent. However, since gonadectomy was not 
evaluated in WT and KOLE mice that underwent IRI, this may be an overstatement. Other 
experiments are needed to thoroughly investigate the hormone-independence and hormonal 
feedback response. It’s important to consider that males and females present genetic differences 
that may have also contributed to our results. Additionally, membrane-bound estrogen receptors 
may act through genetic-independent intracellular pathways. Treatment of a human endothelial 
cell line with E2 culminated with nitric oxide stimulation via PI3-kinase activation of the Akt 
pathway in a gene transactivation-independent ER signaling [184]. Finally, aromatase is also 
known to be expressed in other organs, such as the brain [185], suggesting it is still possible that 
estrogens are mediating the protective effect in Sult1e1 KO and triclosan-treated WT mice. It’s 
paramount to include AKI mice groups treated with a systemic aromatase inhibitor and an estrogen 
receptor antagonist in our analysis. 
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Sex-differences were observed in the results obtained from KOLE mice. Immunostaining 
of these samples suggested a sex-difference in Sult1e1 expression upon IRI. This may have 
contributed to a lack of AKI effect in female KOLE mice. But it is still not clear why a greatly 
induced Sult1e1 expression in livers of female KOLE had no further phenotype effect, hence, no 
increased kidney injury, whereas a not so dramatic increase in livers of female WT was sufficient 
to establish AKI. Although these results in KOLE mice suggest that an enzyme saturation is likely 
occurring, further studies are paramount to understand this effect. Additionally, bioinformatics 
comparisons between male and female kidney-liver crosstalk will also be important to clarify what 
molecule is directly mediating the harmful effect of ischemia and culminating with AKI. Finally, 
because these studies are based in a mouse-model of AKI, evaluation of SULT1E1 expression in 
livers and kidneys from deceased humans and correlation with any degree of kidney damage will 
provide crucial information regarding the importance of this enzyme in human beings and may 
uncover novel therapeutic targets that will benefit millions of those afflicted by kidney disorders.  
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